OCLN (Occludin) is a transmembrane tight junction protein crucial for maintaining [blood-brain barrier](/entities/blood-brain-barrier) (BBB) function. It plays a key role in regulating paracellular permeability and protecting the brain from peripheral molecules [1].
Introduction
Occludin was the first identified tight junction transmembrane protein. It is a 65 kDa protein with four transmembrane domains that forms the structural basis of tight junctions. Unlike claudins, occludin is not essential for tight junction formation but is critical for maintaining barrier function and signaling [2].
Gene Structure
The OCLN gene is located on chromosome 5q13.2 and encodes a protein of 522 amino acids. The gene is expressed in endothelial and epithelial cells throughout the body, with high expression in brain microvascular endothelial cells.
Protein Structure
Occludin has a unique structure:
Four transmembrane domains creating two extracellular loops
N-terminal cytoplasmic domain: Interacts with the actin cytoskeleton
C-terminal cytoplasmic tail: Binds to ZO-1 and other scaffolding proteins
Extracellular loops: Mediate cell-cell adhesion
Normal Physiological Function
Blood-Brain Barrier
Maintains tight junction integrity
Regulates paracellular transport
Controls barrier permeability
Signaling Functions
Participates in tight junction assembly signaling
Responds to inflammatory cytokines
Regulates barrier remodeling
Role in Neurodegeneration
Alzheimer's Disease
OCLN expression is reduced in AD brains
BBB breakdown correlates with neuropathology
[Amyloid-beta](/proteins/amyloid-beta) can disrupt occludin-based barriers [3]
Parkinson's Disease
Contributes to neuroinflammation
May affect drug delivery to the brain
Stroke
Acute disruption of occludin after stroke
Target for neuroprotective therapies
Marker of BBB damage
Multiple Sclerosis
Downregulated in MS lesions
Loss correlates with disease activity
Therapeutic Implications
Drug Delivery
Understanding OCLN regulation can improve BBB targeting
Cytokine modulation can transiently open barriers
Biomarkers
CSF occludin levels indicate BBB damage
Useful for monitoring disease progression
Key Publications
[Cummins, Occludin in barrier function (2012)](https://doi.org/10.1016/j.tcb.2012.01.002). Trends in Cell Biology.
[Hawkins & Davis, The blood-brain barrier in neurodegeneration (2005)](https://doi.org/10.1016/j.pharmthera.2005.01.004). Pharmacology & Therapeutics.
[Sweeney et al., Blood-brain barrier breakdown in Alzheimer's disease (2019)](https://doi.org/10.1038/s41582-019-0167-3). Nature Reviews Neurology.
Background
The study of Ocln — Occludin has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Brain Atlas Resources
[Allen Human Brain Atlas](https://human.brain-map.org/) - Gene expression data across brain regions
[Cummins PM, "Occludin in barrier function." Trends in Cell Biology (2012)](https://doi.org/10.1016/j.tcb.2012.01.002)
[Hawkins BT, Davis TP, "The blood-brain barrier/neurovascular unit in health and disease." Pharmacology & Therapeutics (2005)](https://doi.org/10.1016/j.pharmthera.2005.01.004)
[Sweeney MD, Sagare AP, Zlokovic BV, "Blood-brain barrier breakdown in Alzheimer's disease and other neurodegenerative disorders." Nature Reviews Neurology (2019)](https://doi.org/10.1038/s41582-019-0167-3)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate